Medincell’s Phase 3 trial for long-acting injectable olanzapine in schizophrenia reaches completion

Medincell has announced the successful completion of the pivotal Phase 3 SOLARIS clinical trial for its long-acting injectable olanzapine (LAI), developed in partnership with Teva Pharmaceuticals. This milestone marks a significant advancement in the treatment of schizophrenia, with the potential to reshape therapeutic approaches for patients requiring consistent, long-term symptom management.